Predictors of sinus rhythm 6 weeks after cardioversion of atrial fibrillation: a pre-planned post hoc analysis of the X-VeRT trial

Autor: Cappato, R, Ezekowitz, MD, Hohnloser, SH, Meng, IL, Wosnitza, M, Camm, AJ

AIMS: Using a pre-planned post hoc analysis of patients included in X-VeRT, we evaluated predictors of sinus rhythm at 6 weeks after planned cardioversion. METHODS AND RESULTS: Receiver operating characteristic curves and logistic regression models w

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::4780ed4d8e6e6c3723d7346055e28b41

Predictors of sinus rhythm 6 weeks after cardioversion of atrial fibrillation: a pre-planned post hoc analysis of the X-VeRT trial.

Autor: Cappato R; Arrhythmia & Electrophysiology Center, IRCCS Gruppo MultiMedica, Sesto San Giovanni, Milan, Italy., Ezekowitz MD; The Sidney Kimmel Medical College at Thomas Jefferson University and Lankenau Heart Center and Bryn Mawr Hospital, Philadelphia, PA, USA., Hohnloser SH; Division of Clinical Electrophysiology, Department of Cardiology, J.W. Goethe University, Frankfurt, Germany., Meng IL; Medical Affairs, Bayer AG, Berlin, Germany., Wosnitza M; Medical Affairs, Bayer AG, Berlin, Germany., Camm AAJ; Cardiology Clinical Academic Group, St. George's, University of London, London, UK.

Publikováno v: Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology [Europace] 2021 Oct 09; Vol. 23 (10), pp. 1539-1547.

Left atrial thrombus resolution in non-valvular atrial fibrillation or flutter: biomarker substudy results from a prospective study with rivaroxaban (X-TRA).

Autor: Miyazawa K; a Institute of Cardiovascular Sciences , University of Birmingham , Birmingham , UK., Pastori D; a Institute of Cardiovascular Sciences , University of Birmingham , Birmingham , UK.; b Department of Internal Medicine and Medical Specialties, I Clinica Medica, Atherothrombosis Centre , Sapienza University of Rome , Rome , Italy., Hammerstingl C; c Department of Medicine II , Heart Centre Bonn, University Hospital Bonn , Bonn , Germany., Cappato R; d Humanitas Clinical and Research Centre , Milan , Italy., Meng IL; e Global Medical Affairs, Bayer AG , Berlin , Germany., Kramer F; e Global Medical Affairs, Bayer AG , Berlin , Germany., Cohen A; f Cardiology Department , Assistance publique-Hôpitaux de Paris and Université Pierre-et-Marie-Curie, Saint-Antoine University and Medical School , Paris , France., Schulz A; g Research and Clinical Sciences Statistics, Bayer AG , Berlin , Germany., Eickels MV; e Global Medical Affairs, Bayer AG , Berlin , Germany., Lip GYH; a Institute of Cardiovascular Sciences , University of Birmingham , Birmingham , UK.; h Aalborg Thrombosis Research Unit, Department of Clinical Medicine , Aalborg University , Aalborg , Denmark., Marin F; i Department of Cardiology , Hospital Clínico Universitario Virgen de la Arrixaca, IMIB-Arrixaca, CIBER-CV , Murcia , Spain.

Publikováno v: Annals of medicine [Ann Med] 2018 Sep; Vol. 50 (6), pp. 511-518.

Patient-reported treatment satisfaction and budget impact with rivaroxaban vs. standard therapy in elective cardioversion of atrial fibrillation: a post hoc analysis of the X-VeRT trial.

Autor: Hohnloser SH; Department of Cardiology, Division of Clinical Electrophysiology, J.W. Goethe University, Frankfurt, Germany hohnloser@em.uni-frankfurt.de., Cappato R; Arrhythmia and Electrophysiology Center, IRCCS Humanitas Research Hospital, Milan, Italy Humanitas Gavazzeni Hospital, Bergamo, Italy., Ezekowitz MD; The Sidney Kimell Medical College at Thomas Jefferson University, Philadelphia, PA, USA., Evers T; Bayer Pharma AG, Wuppertal, Germany., Sahin K; ClinStat GmbH, Statistics and Health Economics, Cologne, Germany., Kirchhof P; Centre for Cardiovascular Sciences, School of Clinical and Experimental Medicine, University of Birmingham, SWBH and UHB NHS Trusts, Birmingham, UK Department of Cardiovascular Medicine, Hospital of the University of Münster, Münster, Germany., Meng IL; Global Medical Affairs, Bayer HealthCare, Berlin, Germany., van Eickels M; Global Medical Affairs, Bayer HealthCare, Berlin, Germany., Camm AJ; Division of Clinical Sciences, St George's, University of London, London, UK.

Publikováno v: Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology [Europace] 2016 Feb; Vol. 18 (2), pp. 184-90. Date of Electronic Publication: 2015 Oct 20.

Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation.

Autor: Cappato R; Arrhythmia and Electrophysiology Center, University of Milan, IRCCS Policlinico San Donato, San Donato Milanese, Milan, Italy., Ezekowitz MD; The Sidney Kimell Medical College at Thomas Jefferson University, 1999 Sproul Rd, Suite 25, Broomall, PA 19008, USA michael.ezekowitz@comcast.net., Klein AL; Department of Cardiovascular Medicine, Cleveland Clinic Heart and Vascular Institute, Cleveland, OH, USA., Camm AJ; Division of Clinical Sciences, St George's, University of London, London, UK., Ma CS; Cardiology Division, Beijing AnZhen Hospital, Capital Medical University, Beijing, China., Le Heuzey JY; Division of Cardiology and Arrhythmology, Hôpital Européen Georges Pompidou, Université Paris V René-Descartes, Paris, France., Talajic M; Department of Medicine, Research Center, Montreal Heart Institute, Université de Montréal, Montreal, Canada., Scanavacca M; Arrhythmia Clinical Unit of Heart Institute (InCor), University of São Paulo Medical School, São Paulo, Brazil., Vardas PE; Department of Cardiology, Heraklion University Hospital, Heraklion (Crete), Greece., Kirchhof P; Centre for Cardiovascular Sciences, School of Clinical and Experimental Medicine, University of Birmingham, Birmingham, UK SWBH NHS Trust, Birmingham, UK Department of Cardiovascular Medicine, Hospital of the University of Münster, Münster, Germany., Hemmrich M; Global Medical Affairs, Bayer HealthCare, Berlin, Germany., Lanius V; Global Research and Development Statistics, Bayer HealthCare, Berlin, Germany., Meng IL; Global Medical Affairs, Bayer HealthCare, Berlin, Germany., Wildgoose P; Janssen Scientific Affairs, LLC, Raritan, NJ, USA., van Eickels M; Global Medical Affairs, Bayer HealthCare, Berlin, Germany., Hohnloser SH; Department of Cardiology, Division of Clinical Electrophysiology, J.W. Goethe University, Frankfurt, Germany.

Publikováno v: European heart journal [Eur Heart J] 2014 Dec 14; Vol. 35 (47), pp. 3346-55. Date of Electronic Publication: 2014 Sep 02.